Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

BACKGROUND: A nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United States, Canada, and European Union, as an alternative dosing regimen for several indications. Approvals of this Q4W regimen were based on population pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, G V, Tykodi, S S, Schneider, J G, Garbe, C, Gravis, G, Rashford, M, Agrawal, S, Grigoryeva, E, Bello, A, Roy, A, Rollin, L, Zhao, X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290887/
https://www.ncbi.nlm.nih.gov/pubmed/30215677
http://dx.doi.org/10.1093/annonc/mdy408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290887/
https://www.ncbi.nlm.nih.gov/pubmed/30215677
http://dx.doi.org/10.1093/annonc/mdy408

Ejemplares similares